The CNST Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the Raji B lymphocyte line, with targeted disruption of the CNST gene. Consortin, the encoded protein, is a transmembrane adaptor critical for intracellular connexin trafficking. The polyclonal format provides a heterogeneous knockout pool, minimizing clonal bias and enabling robust loss-of-function studies. This suspension-adapted model is tailored for gap junction and intercellular communication research.
The parental Raji cell line is a human Burkitt lymphoma-derived lymphoblastoid line that is Epstein-Barr virus-positive and grows in suspension. As an antigen-presenting B lymphocyte model, it expresses MHC class II molecules and costimulatory ligands, making it widely used in studies of B-cell malignancies, immune synapse formation, and drug development. Its genetic accessibility and rapid proliferation support large-scale functional assays, including those requiring co-culture with other immune or stromal cells.
Consortin localizes to the Golgi, where it binds connexin 43 (GJA1) and connexin 45 (GJC1), escorting them via Rab GTPase- and SNARE-mediated vesicles along the microtubule and actin cytoskeleton to the plasma membrane. This trafficking requires cooperation with Golgi stacking proteins GRASP65 and GM130. Connexin phosphorylation by protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs) regulates the process. Upon reaching the surface, connexins assemble into gap junction plaques that enable intercellular exchange of ions, metabolites, and small signaling molecules, influencing cellular coupling and homeostasis.
CNST knockout in Raji cells disrupts connexin delivery, impairing gap junction formation and diminishing intercellular communication. In Burkitt lymphoma, such communication defects may promote tumor progression, immune evasion, or drug resistance. Moreover, this model offers a B-lymphocyte platform to investigate connexin-related disorders, including cardiac arrhythmias, skin diseases, and hearing loss, where conserved trafficking mechanisms are implicated. The knockout thus bridges basic cell biology with translational research into how loss of connexin-mediated communication affects B-cell pathophysiology and therapy response.
Researchers can apply these cells in diverse assays: Lucifer Yellow dye transfer to measure gap junction permeability, Western blotting and immunofluorescence to monitor Cx43 expression and subcellular localization, and flow cytometry for surface channel detection. Calcium imaging and co-culture setups with immune or stromal partners reveal real-time communication dynamics. Drug sensitivity, proliferation, and apoptosis assays evaluate the impact of connexin modulation in a B-cell context, supporting drug screening for connexin?targeted agents. For technical assistance, please contact Ascent Research.
